Advertisement

Oral Mucositis

  • Ainaz Sourati
  • Ahmad Ameri
  • Mona Malekzadeh
Chapter

Abstract

Almost no patients that are undergoing radiation therapy of head and neck cancers can run away from radiation-induced oral mucositis, especially if the oral cavity is included in the treatment target. Trotti et al. have confirmed the high incidence of induced oral mucositis in a systematic review with rates of 97% during conventional radiation therapy, 100% during altered fractionation radiation therapy, and 89% during chemoradiation therapy [1]. In a retrospective study of 204 head and neck cancer patients that received radiation therapy with or without chemotherapy, oral mucositis occurred in 91% of patients; the rates of mucositis grades 1, 2, 3, and 4 were 4%, 21%, 60%, and 6%, respectively [2].

Keywords

Oral Mucosa Intensity Modulate Radiation Therapy Oral Mucositis Neck Cancer Patient Keratinocyte Growth Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK et al (2003) Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66(3):253–262PubMedCrossRefGoogle Scholar
  2. 2.
    Elting LS, Keefe DM, Sonis ST, Garden AS, Spijkervet F, Barasch A et al (2008) Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy. Cancer 113(10):2704–2713PubMedCrossRefGoogle Scholar
  3. 3.
    Vera-Llonch M, Oster G, Hagiwara M, Sonis S (2006) Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106(2):329–336PubMedCrossRefGoogle Scholar
  4. 4.
    Squier CA, Kremer MJ (2000) Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr 29:7–15Google Scholar
  5. 5.
    Sonis ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4(4):277–284PubMedCrossRefGoogle Scholar
  6. 6.
    Kumar PS, Balan A, Sankar A, Bose T (2009) Radiation induced oral mucositis. Indian J Palliat Care 15(2):95CrossRefGoogle Scholar
  7. 7.
    Logan RM, Gibson RJ, Sonis ST, Keefe DM (2007) Nuclear factor-κB (NF-κB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 43(4):395–401PubMedCrossRefGoogle Scholar
  8. 8.
    Gibson R, Bowen J, Cummins A, Logan R, Healey T, Keefe D (2004) Ultrastructural changes occur early within the oral mucosa following cancer chemotherapy [abstract A-373]. Supp Care Cancer 12(6):389Google Scholar
  9. 9.
    Denham JW, Hauer-Jensen M (2002) The radiotherapeutic injury—a complex ‘wound’. Radiother Oncol 63(2):129–145PubMedCrossRefGoogle Scholar
  10. 10.
    Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(S9):1995–2025PubMedCrossRefGoogle Scholar
  11. 11.
    Baker DG (1982) The radiobiological basis for tissue reactions in the oral cavity following therapeutic x-irradiation: a review. Arch Otolaryngol 108(1):21–24PubMedCrossRefGoogle Scholar
  12. 12.
    Biswal BM (2008) Current trends in the management of oral mucositis related to cancer treatment. Malays J Med Sci 15(3):4PubMedPubMedCentralGoogle Scholar
  13. 13.
    Shih A, Miaskowski C, Dodd MJ, Stotts NA, MacPhail L (2003) Mechanisms for radiation-induced oral mucositis and the consequences. Cancer Nurs 26(3):222–229PubMedCrossRefGoogle Scholar
  14. 14.
    Köstler WJ, Hejna M, Wenzel C, Zielinski CC (2001) Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment. CA Cancer J Clin 51(5):290–315PubMedCrossRefGoogle Scholar
  15. 15.
    Hilderley L (1997) Principles of teletherapy. In: Hassey-Dow K, Bucholtz J (eds) Nursing care in radiation oncology, 2nd edn. Saunders, Philadelphia, PA, pp 6–20Google Scholar
  16. 16.
    Lalla RV, Sonis ST, Peterson DE (2008) Management of oral mucositis in patients who have cancer. Dent Clin N Am 52(1):61–77PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Rosenthal DI, Trotti A (2009) Strategies for managing radiation-induced mucositis in head and neck cancer. Semin Radiat Oncol 19:29–34PubMedCrossRefGoogle Scholar
  18. 18.
    Peterson D, Bensadoun R-J, Roila F, Group EGW (2011) Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol 22(suppl 6):vi78–vi84PubMedPubMedCentralGoogle Scholar
  19. 19.
    Supportive P, Board PCE. Oral complications of chemotherapy and head/neck radiation (PDQ®). 2016.Google Scholar
  20. 20.
    Seiwert TY, Salama JK, Vokes EE (2007) The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol 4(3):156–171PubMedCrossRefGoogle Scholar
  21. 21.
    Hoffmann W, Belka C, Schmidberger H, Budach W, Bochtler H, Hess CF et al (1997) Radiotherapy and concomitant weekly 1-hour infusion of paclitaxel in the treatment of head and neck cancer—results from a Phase I trial. Int J Rad Oncol Biol Phys 38(4):691–696CrossRefGoogle Scholar
  22. 22.
    Tsan D-L, Lin C-Y, Kang C-J, Huang S-F, Fan K-H, Liao C-T et al (2012) The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol 7(1):1CrossRefGoogle Scholar
  23. 23.
    Musio D, De Felice F, Bulzonetti N, Tombolini V (2013) Cetuximab and oral mucositis: is it different from oral mucositis caused by other drugs? Otolaryngology 2013. doi: 10.4172/2161-119X.1000147
  24. 24.
    Mehra R, Cohen RB, Burtness BA (2008) The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol 6(10):742PubMedPubMedCentralGoogle Scholar
  25. 25.
    Walsh L, Gillham C, Dunne M, Fraser I, Hollywood D, Armstrong J et al (2011) Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol 98(1):38–41PubMedCrossRefGoogle Scholar
  26. 26.
    Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578PubMedCrossRefGoogle Scholar
  27. 27.
    Pryor DI, Porceddu SV, Burmeister BH, Guminski A, Thomson DB, Shepherdson K et al (2009) Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 90(2):172–176PubMedCrossRefGoogle Scholar
  28. 28.
    Narayan S, Lehmann J, Coleman MA, Vaughan A, Yang CC, Enepekides D et al (2008) Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy. Int J Rad Oncol Biol Phys 72(3):756–762CrossRefGoogle Scholar
  29. 29.
    Shogan J, Bhatnagar A, Heron D, Smith R, Andrede R, Huq M et al (2005) Dosimetric correlation of oral cavity dose with acute mucositis in patients treated with intensity modulated radiation therapy (IMRT) and chemotherapy. Int J Radiat Oncol Biol Phys 63:S74–SS5CrossRefGoogle Scholar
  30. 30.
    Budach W, Hehr T, Budach V, Belka C, Dietz K (2006) A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer 6:28PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Russo G, Haddad R, Posner M, Machtay M (2008) Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist 13(8):886–898PubMedCrossRefGoogle Scholar
  32. 32.
    Fu KK et al (1993) A phase III randomized study to compare twice daily hyperfractionation, accelerated hyperfractionation with concomitant boost to standard fractionation radiotherapy for squamous cell carcinomas of the head and neck. Data on file, Radiation Treatment Oncology Group RTOG (90–03). PhiladelphiaGoogle Scholar
  33. 33.
    Horiot J-C, Le Fur R, N’guyen T, Chenal C, Schraub S, Alfonsi S et al (1992) Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol 25(4):231–241PubMedCrossRefGoogle Scholar
  34. 34.
    Mariani S (2001) Management of radiation-induced toxicity in patients with head and neck cancer. Medscape Hematology-Oncology eJournal 4(2)Google Scholar
  35. 35.
    Meirovitz A, Kuten M, Billan S, Abdah-Bortnyak R, Sharon A, Peretz T et al (2010) Cytokines levels, severity of acute mucositis and the need of PEG tube installation during chemo-radiation for head and neck cancer-a prospective pilot study. Radiat Oncol 5(1):1CrossRefGoogle Scholar
  36. 36.
    Naidu MUR, Ramana GV, Rani PU, Suman A, Roy P (2004) Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia 6(5):423–431PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Sonis ST (2013) Oral mucositis in head and neck cancer: risk, biology, and management. Am Soc Clin Oncol Educ Book doi: 10.1200/EdBook_AM.2013.33.e236
  38. 38.
    Miyamoto M (2007) Reducing the incidence and severity of oral mucositis—can it be done? US Oncological Disease 1(2):18–21Google Scholar
  39. 39.
    Ren J-H, Dai X-F, Yan G-L, Jin M, Liu C-W, Yang K-Y et al (2014) Acute oral mucositis in nasopharyngeal carcinoma patients treated with radiotherapy: association with genetic polymorphism in DNA DSB repair genes. Int J Radiat Biol 90(3):256–261PubMedCrossRefGoogle Scholar
  40. 40.
    Venkatesh GH, Manjunath VB, Mumbrekar KD, Negi H, Fernandes DJ, Sharan K et al (2014) Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One 9(3):e89079PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Xanthinaki A, Nicolatou-Galitis O, Athanassiadou P, Gonidi M, Kouloulias V, Sotiropoulou-Lontou A, Pissakas G, Kyprianou K, Kouvaris J, Patsouris E (2008) Apoptotic and inflammation markers in oral mucositis in head and neck cancer patients receiving radiotherapy: preliminary report. Supp Care Cancer 16:1025–1033CrossRefGoogle Scholar
  42. 42.
    Akmansu M, Unsal D, Bora H, Elbeg S (2005) Influence of locoregional radiation treatment on tumor necrosis factor-alpha and interleukin-6 in the serum of patients with head and neck cancer. Cytokine 31:41–45PubMedCrossRefGoogle Scholar
  43. 43.
    Haddad R, Sonis S, Posner M, Wirth L, Costello R, Braschayko P et al (2009) Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer 115(19):4514–4523PubMedCrossRefGoogle Scholar
  44. 44.
    Epstein JB, Gorsky M, Guglietta A, Le N, Sonis ST (2000) The correlation between epidermal growth factor levels in saliva and the severity of oral mucositis during oropharyngeal radiation therapy. Cancer 89(11):2258–2265PubMedCrossRefGoogle Scholar
  45. 45.
    Suresh A, Varma PP, Sinha S, Deepika S, Raman R, Srinivasan M et al (2010) Risk-scoring system for predicting mucositis in patients of head and neck cancer receiving concurrent chemoradiotherapy [rssm-hn]. J Cancer Res Ther 6(4):448PubMedCrossRefGoogle Scholar
  46. 46.
    Gussgard AM, Jokstad A, Hope AJ, Wood R, Tenenbaum H (2015) Radiation induced mucositis in patients with head and neck cancer–should the signs or the symptoms be measured? J Can Dent Assoc 81:f11PubMedGoogle Scholar
  47. 47.
    Soto EF-DJ, DeVita BA (2015) Hellman, and Rosenberg’s cancer: principles & practice of oncology, 10th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  48. 48.
    Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the radiation therapy oncology group (RTOG) and the European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341–1346PubMedCrossRefGoogle Scholar
  49. 49.
    NCI N (2009) DHHS common terminology criteria for adverse events v4. 0. National Cancer Institute, Bethesda, MDGoogle Scholar
  50. 50.
    Organization WH. WHO handbook for reporting results of cancer treatment. 1979.Google Scholar
  51. 51.
    Taylor S (2014) Guidelines for prevention and management of oral mucositis. West Sussex and Hampshire Cancer Network NHS, SurreyGoogle Scholar
  52. 52.
    Devi S, Singh N (2014) Dental care during and after radiotherapy in head and neck cancer. Nat J Maxillofac Surg 5(2):117CrossRefGoogle Scholar
  53. 53.
    Epstein JB, Silverman S, Paggiarino DA, Crockett S, Schubert MM, Senzer NN et al (2001) Benzydamine HCl for prophylaxis of radiation-induced oral mucositis. Cancer 92(4):875–885PubMedCrossRefGoogle Scholar
  54. 54.
    Lalla RV, Schubert MM, Bensadoun R-J, Keefe D (2006) Anti-inflammatory agents in the management of alimentary mucositis. Supp Care Cancer 14(6):558–565CrossRefGoogle Scholar
  55. 55.
    Kazemian A, Kamian S, Aghili M, Hashemi F, Haddad P (2009) Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers: a double-blind placebo-controlled randomized clinical trial. Eur J Cancer Care 18(2):174–178CrossRefGoogle Scholar
  56. 56.
    Sheibani KM, Mafi AR, Moghaddam S, Taslimi F, Amiran A, Ameri A (2015) Efficacy of benzydamine oral rinse in prevention and management of radiation-induced oral mucositis: a double-blind placebo-controlled randomized clinical trial. Asia Pac J Clin Oncol 11(1):22–27PubMedCrossRefGoogle Scholar
  57. 57.
    Kin-Fong CK, Ka TYJ (2005) A pilot study of chlorhexidine and benzydamine oral rinses for the prevention and treatment of irradiation mucositis in patients with head and neck cancer. Cancer Nurs 29(5):423–430CrossRefGoogle Scholar
  58. 58.
    Hanna EY (2002) Prevention of radiation-induced oral mucositis with benzydamine. Curr Oncol Rep 4(1):65–67PubMedCrossRefGoogle Scholar
  59. 59.
    Kouloulias V, Thalassinou S, Platoni K, Zygogianni A, Kouvaris J, Antypas C et al (2013) The treatment outcome and radiation-induced toxicity for patients with head and neck carcinoma in the IMRT era: a systematic review with dosimetric and clinical parameters. Biomed Res Int 2013:401261PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Khuntia D, Harris J, Bentzen S, Kies M, Meyers J, Foote R et al (2008) Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for head and neck cancer: preliminary results of RTOG 0234. Int J Radiat Oncol Biol Phys 72(1):S33CrossRefGoogle Scholar
  61. 61.
    Antunes HS, Herchenhorn D, Small IA, Araújo CM, Viégas CMP, Cabral E et al (2013) Phase III trial of low-level laser therapy to prevent oral mucositis in head and neck cancer patients treated with concurrent chemoradiation. Radiother Oncol 109(2):297–302PubMedCrossRefGoogle Scholar
  62. 62.
    Genot M-T, Klastersky J (2005) Low-level laser for prevention and therapy of oral mucositis induced by chemotherapy or radiotherapy. Curr Opin Oncol 17(3):236–240PubMedCrossRefGoogle Scholar
  63. 63.
    Jadaud E, Bensadoun R (2012) Low-level laser therapy: a standard of supportive care for cancer therapy-induced oral mucositis in head and neck cancer patients? Laser Ther 21(4):297PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Antunes H, Herchenhorn D, Araujo C, Cabral E, Ferreira EdS, Small I, et al (2011) Phase III trial of low-level laser therapy to prevent induced oral mucositis in head and neck cancer patients submitted to concurrent chemoradiation. ASCO Annual Meeting ProceedingsGoogle Scholar
  65. 65.
    Figueiredo ALP, Lins L, Cattony AC, Falcão AFP (2013) Laser therapy in oral mucositis control: a meta-analysis. Rev Assoc Med Bras 59(5):467–474PubMedCrossRefGoogle Scholar
  66. 66.
    Lopes CO, Mas JRI, Zângaro RA (2006) Low level laser therapy in the prevention of radiotherapy-induced xerostomia and oral mucositis. Radiol Bras 39(2):131–136CrossRefGoogle Scholar
  67. 67.
    Arbabi-Kalati F, Arbabi-Kalati F, Moridi T (2013) Evaluation of the effect of low level laser on prevention of chemotherapy-induced mucositis. Acta Med Iran 51(3):157PubMedGoogle Scholar
  68. 68.
    Tezel A, Kara C, Balkaya V, Orbak R (2009) An evaluation of different treatments for recurrent aphthous stomatitis and patient perceptions: Nd: YAG laser versus medication. Photomed Laser Surg 27(1):101–106PubMedCrossRefGoogle Scholar
  69. 69.
    Barrett S (2009) A skeptical look at low level laser therapy. Quackwatch Retrieved 2010–07,23Google Scholar
  70. 70.
    Rouse K, Nwokedi E, Woodliff JE, Epstein J, Klimberg VS (1995) Glutamine enhances selectivity of chemotherapy through changes in glutathione metabolism. Ann Surg 221(4):420PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Savarese DM, Savy G, Vahdat L, Wischmeyer PE, Corey B (2003) Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 29(6):501–513PubMedCrossRefGoogle Scholar
  72. 72.
    Chattopadhyay S, Saha A, Azam M, Mukherjee A, Sur PK (2014) Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: a prospective randomized study. South Asian J Cancer 3(1):8PubMedPubMedCentralCrossRefGoogle Scholar
  73. 73.
    Silverman S Jr (2007) Diagnosis and management of oral mucositis. J Support Oncol 5(2 Suppl 1):13–21PubMedGoogle Scholar
  74. 74.
    Tsujimoto T, Yamamoto Y, Wasa M, Takenaka Y, Nakahara S, Takagi T et al (2015) L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer: a double-blind, randomized, placebo-controlled trial. Oncol Rep 33(1):33–39PubMedGoogle Scholar
  75. 75.
    Vidal-Casariego A, Calleja-Fernández A, Ballesteros-Pomar MD, Cano-Rodríguez I (2013) Efficacy of glutamine in the prevention of oral mucositis and acute radiation-induced esophagitis: a retrospective study. Nutr Cancer 65(3):424–429PubMedCrossRefGoogle Scholar
  76. 76.
    Huang E-Y, Leung SW, Wang C-J, Chen H-C, Sun L-M, Fang F-M et al (2000) Oral glutamine to alleviate radiation-induced oral mucositis: a pilot randomized trial. Int J Radiat Oncol Biol Phys 46(3):535–539PubMedCrossRefGoogle Scholar
  77. 77.
    Brian D, Lawenda MD (2013) Use glutamine to reduce the severity of mucositis and neuropathy (during chemotherapy or radiation therapy). Integrat Oncol Essent 25Google Scholar
  78. 78.
    Moslemi D, Babaee N, Damavandi M, Pourghasem M, Moghadamnia A (2014) Oral zinc sulphate and prevention of radiation-induced oropharyngealmucositis in patients with head and neck cancers: a double blind, randomized controlled clinical trial. Int J Radiat Res 12(3):235–241Google Scholar
  79. 79.
    Putwatana P, Sanmanowong P, Oonprasertpong L, Junda T, Pitiporn S, Narkwong L (2009) Relief of radiation-induced oral mucositis in head and neck cancer. Cancer Nurs 32(1):82–87PubMedCrossRefGoogle Scholar
  80. 80.
    Putwatana P (ed) (2007) Comparison of glycerine payayor and benzydamine in prevention and relief of oral mucositis among patients with head and neck cancer receiving radiotherapy. The 18th International Nursing Research Congress focusing on evidence-based practiceGoogle Scholar
  81. 81.
    Babaee N, Moslemi D, Khalilpour M, Vejdani F, Moghadamnia Y, Bijani A et al (2013) Antioxidant capacity of Calendula officinalis flowers extract and prevention of radiation induced oropharyngeal mucositis in patients with head and neck cancers: a randomized controlled clinical study. DARU J Pharmaceut Sci 21(1):1CrossRefGoogle Scholar
  82. 82.
    Babaee N, Moslemi D, Khalilpour M, Vejdani F, Bijani A, Moghadamnia AA, et al (2013) Investigation of the effect of Calendula officinalis extract on preventing radiotherapy-induced oral mucositis. Reports of Radiotherapy and Oncology 1(1)Google Scholar
  83. 83.
    Maiti P, Ray A, Mitra T, Jana U, Bhattacharya J, Ganguly S (2012) The effect of honey on mucositis induced by chemoradiation in head and neck cancer. J Indian Med Assoc 110(7):453–456PubMedGoogle Scholar
  84. 84.
    Richards D (2012) Evidence to support the use of honey for prevention of oral mucositis in cancer patients is limited. Evid Based Dent 13(3):74PubMedCrossRefGoogle Scholar
  85. 85.
    Hawley P, Hovan A, McGahan CE, Saunders D (2014) A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Supp Care Cancer 22(3):751–761CrossRefGoogle Scholar
  86. 86.
    Erdem Ö, Güngörmüs Z (2014) The effect of royal jelly on oral mucositis in patients undergoing radiotherapy and chemotherapy. Holist Nurs Pract 28(4):242–246PubMedCrossRefGoogle Scholar
  87. 87.
    Raoul J-L, Cadre B, Le Prisé E, Boucher E (2003) Local injections of granulocyte-macrophage colony-stimulating factor (Gm-CSF) for the treatment of radiation-induced mucosa ulcers. Radiother Oncol 68(3):303–304PubMedCrossRefGoogle Scholar
  88. 88.
    Masucci G, Broman P, Kelly C, Lindahl S, Malmberg L, Reizenstein J et al (2005) Therapeutic efficacy by recombinant human granulocyte/monocyte-colony stimulating factor on mucositis occurring in patients with oral and oropharynx tumors treated with curative radiotherapy. Med Oncol 22(3):247–256PubMedCrossRefGoogle Scholar
  89. 89.
    Wagner W, Alfrink M, Haus U, Matt J (1998) Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer. Anticancer Res 19(1B):799–803Google Scholar
  90. 90.
    Nicolatou O, Sotiropoulou-Lontou A, Skarlatos J, Kyprianou K, Kolitsi G, Dardoufas K (1998) A pilot study of the effect of granulocyte–macrophage colony–stimulating factor on oral mucositis in head and neck cancer patients during x-radiation therapy: a preliminary report. Int J Radiat Oncol Biol Phys 42(3):551–556PubMedCrossRefGoogle Scholar
  91. 91.
    Rovirosa A, Ferre J, Biete A (1998) Granulocyte macrophage–colony–stimulating factor mouthwashes heal oral ulcers during head and neck radiotherapy. Int J Radiat Oncol Biol Phys 41(4):747–754PubMedCrossRefGoogle Scholar
  92. 92.
    Saarilahti K, Kajanti M, Joensuu T, Kouri M, Joensuu H (2002) Comparison of granulocyte-macrophage colony-stimulating factor and sucralfate mouthwashes in the prevention of radiation-induced mucositis: a double-blind prospective randomized phase III study. Int J Radiat Oncol Biol Phys 54(2):479–485PubMedCrossRefGoogle Scholar
  93. 93.
    McAleese J, Bishop K, A’Hern R, Henk J (2014) Randomized phase II study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer. Br J Radiol 74:608–613Google Scholar
  94. 94.
    Hoffman KE, Pugh SL, James JL, Scarantino C, Movsas B, Valicenti RK et al (2014) The impact of concurrent granulocyte–macrophage colony-stimulating factor on quality of life in head and neck cancer patients: results of the randomized, placebo-controlled radiation therapy oncology group 9901 trial. Qual Life Res 23(6):1841–1858PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Barasch A, Epstein J, Tilashalski K (2009) Palifermin for management of treatment-induced oral mucositis in cancer patients. Biologics 3:111–116PubMedPubMedCentralGoogle Scholar
  96. 96.
    Brizel D, Herman T, Goffinet D, Sailer S, Agarwala S, Schwartz G et al (2001) A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head & neck cancer (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CCT). Int J Radiat Oncol Biol Phys 51(3):40CrossRefGoogle Scholar
  97. 97.
    Brizel DM, Murphy BA, Rosenthal DI, Pandya KJ, Glück S, Brizel HE et al (2008) Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. J Clin Oncol 26(15):2489–2496PubMedCrossRefGoogle Scholar
  98. 98.
    Ning S, Shui C, Khan WB, Benson W, Lacey DL, Knox SJ (1998) Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys 40(1):177–187PubMedCrossRefGoogle Scholar
  99. 99.
    Hong J, LEE SW, Song S, Ahn S, Shin S, Choi E et al (2009) Recombinant human epidermal growth factor treatment of radiation-induced severe oral mucositis in patients with head and neck malignancies. Eur J Cancer Care 18(6):636–641CrossRefGoogle Scholar
  100. 100.
    Lee S-w, Jung KI, Kim YW, Jung HD, Kim HS, Hong JP (2007) Effect of epidermal growth factor against radiotherapy-induced oral mucositis in rats. Int J Radiat Oncol Biol Phys 67(4):1172–1178PubMedCrossRefGoogle Scholar
  101. 101.
    Ara G, Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST et al (2008) Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol 84(5):401–412PubMedCrossRefGoogle Scholar
  102. 102.
    Kouvaris JR, Kouloulias VE, Vlahos LJ (2007) Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist 12(6):738–747PubMedCrossRefGoogle Scholar
  103. 103.
    Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P et al (2013) Systematic review of amifostine for the management of oral mucositis in cancer patients. Supp Care Cancer 21(1):357–364CrossRefGoogle Scholar
  104. 104.
    Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, Dardoufas K, Kouloulias V, Kyprianou K et al (2006) Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Supp Care Cancer 14(1):44–51CrossRefGoogle Scholar
  105. 105.
    Mücke R, Kaben U, Libera T, Knauerhase H, Ziegler P, Hamann D et al (1996) Use of fluconazole as antimycotic prophylaxis in radiotherapy of patients with head and neck tumors. Mycoses 40:53–55CrossRefGoogle Scholar
  106. 106.
    Gava A, Ferrarese F, Tonetto V, Coghetto F, Marazzato G, Zorat P (1996) Can the prophylactic treatment of mycotic mucositis improve the time of performing radiotherapy in head and neck tumors? Radiol Med 91(4):452–455PubMedGoogle Scholar
  107. 107.
    Koc M, Aktas E (2003) Prophylactic treatment of mycotic mucositis in radiotherapy of patients with head and neck cancers. Jpn J Clin Oncol 33(2):57–60PubMedCrossRefGoogle Scholar
  108. 108.
    Jham BC, da Silva Freire AR (2006) Oral complications of radiotherapy in the head and neck. Rev Bras Otorrinolaringol 72(5):704–708CrossRefGoogle Scholar
  109. 109.
    Sharma A, Rath G, Chaudhary S, Thakar A, Mohanti BK, Bahadur S (2012) Lactobacillus brevis CD2 lozenges reduce radiation-and chemotherapy-induced mucositis in patients with head and neck cancer: a randomized double-blind placebo-controlled study. Eur J Cancer 48(6):875–881PubMedCrossRefGoogle Scholar
  110. 110.
    Satheeshkumar P, Chamba MS, Balan A, Sreelatha K, Bhatathiri V, Bose T (2010) Effectiveness of triclosan in the management of radiation-induced oral mucositis: a randomized clinical trial. J Cancer Res Ther 6(4):466PubMedCrossRefGoogle Scholar
  111. 111.
    Symonds R, McIlroy P, Khorrami J, Paul J, Pyper E, Alcock S et al (1996) The reduction of radiation mucositis by selective decontamination antibiotic pastilles: a placebo-controlled double-blind trial. Br J Cancer 74(2):312PubMedPubMedCentralCrossRefGoogle Scholar
  112. 112.
    Spijkervet FK, Van Saene HK, Van Saene JJ, Panders AK, Vermey A, Mehta DM et al (1991) Effect of selective elimination of the oral flora on mucositis in irradiated head and neck cancer patients. J Surg Oncol 46(3):167–173PubMedCrossRefGoogle Scholar
  113. 113.
    Okuno SH, Foote RL, Loprinzi CL, Gulavita S, Sloan JA, Earle J et al (1997) A randomized trial of a nonabsorbable antibiotic lozenge given to alleviate radiation-induced mucositis. Cancer 79(11):2193–2199PubMedCrossRefGoogle Scholar
  114. 114.
    Oguchi M, Shikama N, Sasaki S, Gomi K, Katsuyama Y, Ohta S et al (1998) Mucosa-adhesive water-soluble polymer film for treatment of acute radiation-induced oral mucositis. Int J Radiat Oncol Biol Phys 40(5):1033–1037PubMedCrossRefGoogle Scholar
  115. 115.
    Foote RL, Loprinzi CL, Frank AR, O’Fallon JR, Gulavita S, Tewfik HH et al (1994) Randomized trial of a chlorhexidine mouthwash for alleviation of radiation-induced mucositis. J Clin Oncol 12(12):2630–2633PubMedCrossRefGoogle Scholar
  116. 116.
    Makkonen TA, Boström P, Vilja P, Joensuu H (1994) Sucralfate mouth washing in the prevention of radiation-induced mucositis: a placebo-controlled double-blind randomized study. Int J Radiat Oncol Biol Phys 30(1):177–182PubMedCrossRefGoogle Scholar
  117. 117.
    Franzén L, Henriksson R, Littbrand B, Zackrisson B (1995) Effects of sucralfate on mucositis during and following radiotherapy of malignancies in the head and neck region: a double-blind placebo-controlled study. Acta Oncol 34(2):219–223PubMedCrossRefGoogle Scholar
  118. 118.
    Lievens Y, Haustermans K, Van den Weyngaert D, Van den Bogaert W, Scalliet P, Hutsebaut L et al (1998) Does sucralfate reduce the acute side-effects in head and neck cancer treated with radiotherapy? A double-blind randomized trial. Radiother Oncol 47(2):149–153PubMedCrossRefGoogle Scholar
  119. 119.
    Carter DL, Hebert ME, Smink K, Leopold KA, Clough RL, Brizel DM (1999) Double blind randomized trial of sucralfate vs placebo during radical radiotherapy for head and neck cancers. Head Neck 21(8):760–766PubMedCrossRefGoogle Scholar
  120. 120.
    Etiz D, Erkal H, Serin M, Küçük B, Heparı A, Elhan A et al (2000) Clinical and histopathological evaluation of sucralfate in prevention of oral mucositis induced by radiation therapy in patients with head and neck malignancies. Oral Oncol 36(1):116–120PubMedCrossRefGoogle Scholar
  121. 121.
    Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P et al (2013) Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Supp Care Cancer 21(11):3179–3189CrossRefGoogle Scholar
  122. 122.
    Veness M, Foroudi F, Gebski V, Timms I, Sathiyaseelan Y, Cakir B et al (2006) Use of topical misoprostol to reduce radiation-induced mucositis: results of a randomized, double-blind, placebo-controlled trial. Australas Radiol 50(5):468–474PubMedCrossRefGoogle Scholar
  123. 123.
    Goyal M, Shukla P, Gupta D, Bisht SS, Dhawan A, Gupta S et al (2009) Oral mucositis in morning vs. evening irradiated patients: a randomised prospective study. Int J Radiat Biol 85(6):504–509PubMedCrossRefGoogle Scholar
  124. 124.
    Bjarnason GA, MacKenzie RG, Nabid A, Hodson ID, El-Sayed S, Grimard L et al (2009) Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer: a prospective randomized trial of the National Cancer Institute of Canada clinical trials group (HN3). Int J Radiat Oncol Biol Phys 73(1):166–172PubMedCrossRefGoogle Scholar
  125. 125.
    Jensen SB, Jarvis V, Zadik Y, Barasch A, Ariyawardana A, Hovan A et al (2013) Systematic review of miscellaneous agents for the management of oral mucositis in cancer patients. Supp Care Cancer 21(11):3223–3232CrossRefGoogle Scholar
  126. 126.
    Cassileth B, Yarett I (2012) Antioxidant supplementation in patients with cancer: is it safe and effective? The ASCO Post 3:15Google Scholar
  127. 127.
    Chambers M, Welsh D, Scrimger R, Zehn W, Epstein J, Troha J, et al (eds) (2006) RK-0202 for radiation-induced oral mucositis. ASCO Annual Meeting ProceedingsGoogle Scholar
  128. 128.
    Soref CM, Fahl WE (2014) A new topical vasoconstrictor–based strategy for prevention of oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol 117(4):454–461PubMedCrossRefGoogle Scholar
  129. 129.
    Wong KH, Kuciejewska A, Sharabiani MT, Ng-Cheng-Hin B, Hoy S, Hurley T et al (2017) A randomised controlled trial of Caphosol mouthwash in management of radiation-induced mucositis in head and neck cancer. Radiother Oncol 122:207–211PubMedCrossRefGoogle Scholar
  130. 130.
    Rao NG, Trotti A, Kim J, Schell MJ, Zhao X, Amdur RJ et al (2014) Phase II multicenter trial of Caphosol for the reduction of mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol 50(8):765–769PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Xu J, Yan R, Zhuo P-Y, Li R-R, Ge H-X, Lu W-F (2014) Effectiveness of oxygen nebulization at preventing radiotherapy-induced mucositis in patients with nasopharyngeal cancer. Int J Nurs Sci 1(2):176–179Google Scholar
  132. 132.
    Chang JW, Choi JW, Lee BH, Park JK, Shin YS, Oh Y-T et al (2014) Protective effects of Korean red ginseng on radiation-induced oral mucositis in a preclinical rat model. Nutr Cancer 66(3):400–407PubMedCrossRefGoogle Scholar
  133. 133.
    Maddocks-Jennings W, Wilkinson JM, Cavanagh HM, Shillington D (2009) Evaluating the effects of the essential oils Leptospermum scoparium (manuka) and Kunzea ericoides (kanuka) on radiotherapy induced mucositis: a randomized, placebo controlled feasibility study. Eur J Oncol Nurs 13(2):87–93PubMedCrossRefGoogle Scholar
  134. 134.
    Talaipour A, Hadad P, Sahba S, Sakhdari S (2000) Chamomile mouth rinse effects on mucositis reduction after radiotherapy. J Dent Med 13(1):57–62Google Scholar
  135. 135.
    Ameri A, Heydarirad G, Mahdavi Jafari J, Ghobadi A, Rezaeizadeh H, Choopani R (2015) Medicinal plants contain mucilage used in traditional Persian medicine (TPM). Pharm Biol 53(4):615–623PubMedCrossRefGoogle Scholar
  136. 136.
    Ameri A, Heydarirad G, Rezaeizadeh H, Choopani R, Ghobadi A, Gachkar L (2016) Evaluation of efficacy of an herbal compound on dry mouth in patients with head and neck cancers a randomized clinical trial. J Evid Based Complementary Altern Med 21:30–33PubMedCrossRefGoogle Scholar
  137. 137.
    Iglesias-Bartolome R, Patel V, Cotrim A, Leelahavanichkul K, Molinolo AA, Mitchell JB et al (2012) mTOR inhibition prevents epithelial stem cell senescence and protects from radiation-induced mucositis. Cell Stem Cell 11(3):401–414PubMedPubMedCentralCrossRefGoogle Scholar
  138. 138.
    Han G, Bian L, Li F, Cotrim A, Wang D, Lu J et al (2013) Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nat Med 19(4):421–428PubMedPubMedCentralCrossRefGoogle Scholar
  139. 139.
    Dörr W, Herrmann T (2007) Efficacy of Wobe-Mugos® E for reduction of oral mucositis after radiotherapy. Strahlenther Onkol 183(3):121–127PubMedCrossRefGoogle Scholar
  140. 140.
    ORAL MUCOSITIS - BC Cancer Agency [Internet] (2013) Available from www.bccancer.bc.ca/nursing
  141. 141.
    Roopashri G, Jayanthi K, Guruprasad R (2011) Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: a drug trail. Contemp Clin Dent 2(1):8–12PubMedPubMedCentralCrossRefGoogle Scholar
  142. 142.
    Berger AM, Shuster JL, Von Roenn JH (2013) Principles and practice of palliative care and supportive oncology. Lippincott Williams & Wilkins, Philadelphia, PAGoogle Scholar
  143. 143.
    Leenstra JL, Miller RC, Qin R, Martenson JA, Dornfeld KJ, Bearden JD et al (2014) Doxepin rinse versus placebo in the treatment of acute oral mucositis pain in patients receiving head and neck radiotherapy with or without chemotherapy: a phase III, randomized, double-blind trial (NCCTG-N09C6 [alliance]). J Clin Oncol 32(15):1571–1577PubMedPubMedCentralCrossRefGoogle Scholar
  144. 144.
    Moynihan TJ I have mouth sores from receiving chemotherapy. I’ve heard that something called “magic mouthwash” might help. What is it?Google Scholar
  145. 145.
    Healing E, No O. (2009) Pharmacist’s letter/prescriber’s letterGoogle Scholar
  146. 146.
    Hadjieva T, Cavallin-Ståhl E, Linden M, Tiberg F (2014) Treatment of oral mucositis pain following radiation therapy for head-and-neck cancer using a bioadhesive barrier-forming lipid solution. Supp Care Cancer 22(6):1557–1562CrossRefGoogle Scholar
  147. 147.
    Tiberg F C-S, Linden L, Thuresson K, Hadjieva T (2009) Treatment of oral mucositis pain by a bioadhesive barrier-forming lipid solution. MASCC International Symposium; Rome, Italy, JuneGoogle Scholar
  148. 148.
    Naidu MURG, Ratnam SV, Sudhavani T, Naidu KJ, Roy P, Suresh P, Rani PU, Mohan IK (2005) A randomised, double-blind, parallel, placebo-controlled study to evaluate the efficacy of MF 5232 (Mucotrol), a concentrated oral gel wafer, in the treatment of oral mucositis. Drugs R D 6(5):291–298PubMedCrossRefGoogle Scholar
  149. 149.
    FDA approvals: mucotrol, clindesse, multihance, and others [Internet]. (2016) Available from www.mdscape.com
  150. 150.
    Acetylcysteine rinse in reducing saliva thickness and mucositis in patients with head and neck cancer undergoing radiation therapy [Internet]. Available from Clinical Trials.gov
  151. 151.
    Ahmedzai S, Brooks D, Group T-FCT (1997) Transdermal fentanyl versussustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. J Pain Symptom Manag 13(5):254–261CrossRefGoogle Scholar
  152. 152.
    Coluzzi PH, Schwartzberg L, Conroy JD, Charapata S, Gay M, Busch MA et al (2001) Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain 91(1):123–130PubMedCrossRefGoogle Scholar
  153. 153.
    Gupta A, Duckles B, Giordano J (2009) Use of sublingual methadone for treating pain of chemotherapy-induced oral mucositis. J Opioid Manag 6(1):67–69CrossRefGoogle Scholar
  154. 154.
    Darwish M, Kirby M, Robertson P, Tracewell W, Jiang JG (2007) Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis. Clin Drug Invest 27(9):605–611CrossRefGoogle Scholar
  155. 155.
    Sarvizadeh M, Hemati S, Meidani M, Ashouri M, Roayaei M, Shahsanai A (2015) Morphine mouthwash for the management of oral mucositis in patients with head and neck cancer. Adv Biomed Res 4:44PubMedPubMedCentralCrossRefGoogle Scholar
  156. 156.
    Vayne-Bossert P, Escher M, de Vautibault CG, Dulguerov P, Allal A, Desmeules J et al (2010) Effect of topical morphine (mouthwash) on oral pain due to chemotherapy-and/or radiotherapy-induced mucositis: a randomized double-blinded study. J Palliat Med 13(2):125–128PubMedCrossRefGoogle Scholar
  157. 157.
    Bar Ad V, Weinstein G, Dutta PR, Dosoretz A, Chalian A, Both S et al (2010) Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. Cancer 116(17):4206–4213PubMedCrossRefGoogle Scholar
  158. 158.
    Barker G, Loftus L, Cuddy P, Barker B (1991) The effects of sucralfate suspension and diphenhydramine syrup plus kaolin-pectin on radiotherapy-induced mucositis. Oral Surg Oral Med Oral Pathol 71(3):288–293PubMedCrossRefGoogle Scholar
  159. 159.
    Baharvand M, Hamian M, Moosavizadeh M, Mortazavi A, Ameri A (2015) Phenytoin mouthwash to treat cancer therapy-induced oral mucositis: a pilot study. Indian J Cancer 52(1):81PubMedCrossRefGoogle Scholar
  160. 160.
    Lowry F (2015) Laser treatment halts oral mucositis in its tracks. Oncology Nursing Society (ONS) 40th Annual Congress 2015Google Scholar
  161. 161.
    Treatment of oropharyngeal and esophageal candidiasis [Internet]. Available from www.uptodate.com
  162. 162.
    Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, Sotiropoulou-Lontou A, Dardoufas K, Polychronopoulou A et al (2006) Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Supp Care Cancer 14(7):753–762CrossRefGoogle Scholar
  163. 163.
    Fitzmorris KL, Greene JN, Sandin RL, Field T (2000) Recognition and management of herpes simplex mucositis in neutropenic patients. Inf Med 17(6):413–416Google Scholar
  164. 164.
    Treatment of herpes simplex virus type 1 infection in immune competent patients. Uptodate 2015 [Internet]. Available from www.uptodate.com
  165. 165.
    Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68(4):1110–1120PubMedCrossRefGoogle Scholar
  166. 166.
    Deng G, Cassileth BR (2013) Supportive care and quality of life. Perez and Brady’s principles and practice of radiation oncology. 6th edn. Philadelphia, PA, Lippincott Williams & Wilkins, Section V, Chapter 97Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Ainaz Sourati
    • 1
  • Ahmad Ameri
    • 1
  • Mona Malekzadeh
    • 2
  1. 1.Department of Clinical OncologyImam Hossein Educational Hospital, Shahid Beheshti University of Medical Sciences (SBMU)TehranIran
  2. 2.Department of Radiotherapy and OncologyShohadaye Tajrish Educational Hospital Shahid Beheshti University of Medical Sciences (SBMU)TehranIran

Personalised recommendations